Sign up to save your podcasts
Or
Share Why Biopharma Needs to Tell Better Stories on Novel Drugs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why Biopharma Needs to Tell Better Stories on Novel Drugs
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.
View all episodes
By RBC Capital Markets
5
1212 ratings
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.
More shows like Pathfinders in Biopharma
View all
Pardon My Take
81,757 Listeners
The Daily
112,814 Listeners
Up First from NPR
56,140 Listeners
The Readout Loud
314 Listeners
Making Sense
57 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
27 Listeners
RBC's Markets in Motion
39 Listeners
Biotech Hangout
9 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
Macro Minutes
1 Listeners
Strategic Alternatives
17 Listeners
Goldman Sachs The Markets
76 Listeners
The BioCentury Show
11 Listeners